A3P Biomedical recruits new CEO to lead commercial expansion

STOCKHOLM, June 18, 2021. A3P Biomedical appoints David Rosén as new CEO to lead the commercial expansion of the company’s novel Stockholm3 test for early detection of prostate cancer.  David brings more than 20 years’ experience from the medical device industry, including senior international positions at Getinge and Cantel Medical.

A3P Biomedical is commercializing Stockholm3, a blood test for early detection of aggressive prostate cancer. Based on several large clinical studies, including in total more than 75,000 men, Stockholm3 has significant advantages to currently available tests. Stockholm3 is available at several leading Nordic healthcare providers and the preparations for global expansion are ongoing.

Effective from June, David Rosén is appointed as CEO to lead the commercial expansion of the company. David brings extensive commercial leadership experience from the medical device industry.  At Cantel Medical, David was the President for Continental Europe, Middle East and Asia Pacific, managing the growth of a $230 million business. At Getinge, David held commercial leadership positions in Europe as well as the Asia-Pacific region. David also brings start-up and entrepreneurial experience from Cellectricon and Neoventa.

Martin Steinberg, the co-founding CEO of A3P Biomedical, assumes a role as VP of Corporate Development and continues to serve as Director of the Board.

“I am very pleased that we have been able to recruit David Rosén as our new CEO. With his broad experience from the industry and from heading successful commercial organizations world-wide, he is in a great position to lead the global expansion of A3P Biomedical. I also want to thank Martin Steinberg for his successful work as the founding CEO of A3P. It is excellent that he continues to contribute to the development of A3P” said Thomas Pollare, Chairman of the Board at A3P Biomedical.

“I am excited to join the A3P Biomedical team. Based on strong scientific data, we are uniquely positioned to radically improve early detection of prostate cancer. The Stockholm3 test has the potential to make a real difference in a disease area affecting all men”, said David Rosén, CEO at A3P Biomedical.

For additional information, please contact:
David Rosén, CEO
telephone: +46 10 1823325
email: david.rosen@a3pbiomedical.com

Martin Steinberg, VP Corporate Development
telephone: +46 10 1823327
email: martin.steinberg@a3pbiomedical.com

About Stockholm3
Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer. Stockholm3 finds 100 percent more aggressive prostate cancers and reduce 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the pivotal study, including 58,000 men, was published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Patients benefit from a more precise test (with increased sensitivity and specificity) and healthcare providers benefit from direct cost savings of 17 to 28 percent (1).

(1) Publications, results and clinical validation.

 About prostate cancer
Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. In 2020, 1.4 million men are expected to be diagnosed with prostate cancer and 378,000 deaths are expected. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

About A3P Biomedical, www.a3p.com
A3P Biomedical’s mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics.

The company’s lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden.